The p21 codon 31*C- and DRD2 codon 313*T-related genotypes/alleles, but not XRCC1 codon 399, hOGG1 codon 326, and DRD1-48 polymorphisms, are correlated with the presence of leiomyoma.
OBJECTIVE
To investigate whether the gene polymorphisms for p21, X-ray repair cross-complementing group 1 (XRCC1), human 8-oxoguanine glycosylase 1 (hOGG1), and dopamine D1 and D2 receptors (DRD1, -2) are associated with leiomyoma susceptibility.


METHODS
Prospective study.


METHODS
Departments of gynecology and genetics in a medical center.


METHODS
Women were divided into two groups: leiomyoma (n = 120) and nonleiomyoma (n = 112).


METHODS
The p21 codon 31, XRCC1 codon 399, hOGG1 codon 326, DRD1-48, and DRD2 codon 313 polymorphisms were genotyped by polymerase chain reaction with restriction enzyme digestions (Blp I, MspI, Fnu4HI, Dde I, and NcoI, respectively).


METHODS
Genotypes and allelic frequencies.


RESULTS
The p21 codon 31(*)C- and DRD2 codon 313(*)T-related genotypes/alleles were associated with the presence of leiomyomas. The proportions of p21(*)CC/CA/AA and DRD2(*)CC/CT/TT in both groups were 27.5/68.3/4.2% and 12.5/51.7/35.8% (leiomyoma); and 14.3/51.8/33.9% and 33.9/40.2/25.9% (nonleiomyoma). XRCC1, hOGG1, and DRD1 were not correlated with the presence of leiomyomas. XRCC1(*)GG/GA/AA, hOGG1(*)TT/TA/AA, and DRD1(*)GG/GA/AA were 54.2/37.5/8.3%, 36.7/44.2/19.1%, and 3.3/25.8/70.8% (leiomyoma); and 48.2/47.3/4.5%, 43.6/41/15.4%, and 3.6/25/71.4% (nonleiomyoma).


CONCLUSIONS
The p21 codon 31(*)C- and DRD2 codon 313(*)T-related genotypes/alleles were associated with the presence of leiomyoma. XRCC1, hOGG1, and DRD1 were not correlated with leiomyoma development.
Hsieh
Yao-Yuan
YY
Department of Obstetrics and Gynecology, China Medical University Hospital, Taipei, Taiwan, People's Republic of China.
Chang
Chi-Chen
CC
Bau
Da-Tian
DT
Tsai
Fuu-Jen
FJ
Tsai
Chang-Hai
CH
Chen
Chih-Ping
CP
D016022:Case-Control Studies; D003062:Codon; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics*; D045647:DNA Glycosylases / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D007889:Leiomyoma / Q000201:enzymology / Q000235:genetics*; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D017447:Receptors, Dopamine D1 / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D014594:Uterine Neoplasms / Q000201:enzymology / Q000235:genetics*; D000076105:X-ray Repair Cross Complementing Protein 1
C493956:CDKN1A protein, human; D003062:Codon; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004268:DNA-Binding Proteins; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D045647:DNA Glycosylases; C479058:oxoguanine glycosylase 1, human